JP2020532572A5 - - Google Patents

Info

Publication number
JP2020532572A5
JP2020532572A5 JP2020513799A JP2020513799A JP2020532572A5 JP 2020532572 A5 JP2020532572 A5 JP 2020532572A5 JP 2020513799 A JP2020513799 A JP 2020513799A JP 2020513799 A JP2020513799 A JP 2020513799A JP 2020532572 A5 JP2020532572 A5 JP 2020532572A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
antibody
sequence described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020513799A
Other languages
English (en)
Japanese (ja)
Other versions
JP7277439B2 (ja
JP2020532572A (ja
Filing date
Publication date
Priority claimed from PCT/EP2017/072386 external-priority patent/WO2019048040A1/en
Application filed filed Critical
Publication of JP2020532572A publication Critical patent/JP2020532572A/ja
Publication of JP2020532572A5 publication Critical patent/JP2020532572A5/ja
Priority to JP2023076556A priority Critical patent/JP7882806B2/ja
Application granted granted Critical
Publication of JP7277439B2 publication Critical patent/JP7277439B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020513799A 2017-09-06 2018-09-05 癌の診断に有用な抗体 Active JP7277439B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023076556A JP7882806B2 (ja) 2017-09-06 2023-05-08 癌の診断に有用な抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2017/072386 WO2019048040A1 (en) 2017-09-06 2017-09-06 ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER
EPPCT/EP2017/072386 2017-09-06
PCT/EP2018/073883 WO2019048489A1 (en) 2017-09-06 2018-09-05 ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023076556A Division JP7882806B2 (ja) 2017-09-06 2023-05-08 癌の診断に有用な抗体

Publications (3)

Publication Number Publication Date
JP2020532572A JP2020532572A (ja) 2020-11-12
JP2020532572A5 true JP2020532572A5 (cg-RX-API-DMAC10.html) 2022-04-27
JP7277439B2 JP7277439B2 (ja) 2023-05-19

Family

ID=59858709

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020513799A Active JP7277439B2 (ja) 2017-09-06 2018-09-05 癌の診断に有用な抗体
JP2023076556A Active JP7882806B2 (ja) 2017-09-06 2023-05-08 癌の診断に有用な抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023076556A Active JP7882806B2 (ja) 2017-09-06 2023-05-08 癌の診断に有用な抗体

Country Status (15)

Country Link
US (3) US11279757B2 (cg-RX-API-DMAC10.html)
EP (2) EP3679069B1 (cg-RX-API-DMAC10.html)
JP (2) JP7277439B2 (cg-RX-API-DMAC10.html)
KR (2) KR20230107371A (cg-RX-API-DMAC10.html)
CN (3) CN115433283B (cg-RX-API-DMAC10.html)
AU (2) AU2018327587B2 (cg-RX-API-DMAC10.html)
BR (1) BR112020003694B1 (cg-RX-API-DMAC10.html)
CA (1) CA3073157A1 (cg-RX-API-DMAC10.html)
ES (1) ES2998108T3 (cg-RX-API-DMAC10.html)
IL (2) IL293017A (cg-RX-API-DMAC10.html)
MX (2) MX393242B (cg-RX-API-DMAC10.html)
PL (1) PL3679069T3 (cg-RX-API-DMAC10.html)
SG (1) SG11202000961SA (cg-RX-API-DMAC10.html)
WO (2) WO2019048040A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202000851B (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2404936A1 (en) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
WO2019048040A1 (en) 2017-09-06 2019-03-14 Ganymed Pharmaceuticals Gmbh ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER
CA3177215C (en) 2017-09-29 2026-06-09 Daiichi Sankyo Company, Limited Antibody-pyrrolobenzodiazepine derivative conjugate
CN119708241A (zh) 2019-02-15 2025-03-28 因特格尔莫来库乐有限公司 密封蛋白6抗体及其用途
IL307744A (en) * 2021-04-22 2023-12-01 Astellas Pharma Inc Anti-CLDN4/anti-CD137 bispecific antibody
JP2025528148A (ja) * 2022-08-09 2025-08-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア クローディン-6抗体及びそのコンジュゲート及び使用
CN120282987A (zh) 2022-11-30 2025-07-08 因特格尔莫来库乐有限公司 包括双特异性型式的针对紧密连接蛋白6的抗体
KR20260015262A (ko) 2023-05-25 2026-02-02 더 리전트 오브 더 유니버시티 오브 캘리포니아 암 치료를 위한 클라우딘-6 접합체의 투여량
TW202542202A (zh) * 2024-01-04 2025-11-01 美商翰森生物有限責任公司 抗體、抗原結合片段及其醫療用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
KR100944575B1 (ko) 2002-10-17 2010-02-25 젠맵 에이/에스 Cd20에 대한 인간 모노클로날 항체
AU2004272607B2 (en) * 2003-09-11 2008-11-06 Cornerstone Therapeutics Inc. Monoclonal antibodies against HMGB1
US20100129929A1 (en) * 2006-07-27 2010-05-27 Roberto Polakewicz Tyrosine Phosphorylation Sites
RU2537245C2 (ru) * 2006-10-12 2014-12-27 Чугаи Сейяку Кабусики Кайся Диагностика и лечение злокачественной опухоли с использованием антитела против ereg
WO2009028663A1 (ja) * 2007-08-30 2009-03-05 Kyowa Hakko Kirin Co., Ltd. 抗Claudin-3抗体
AU2009203464A1 (en) * 2008-01-11 2009-07-16 Forerunner Pharma Research Co., Ltd. Anti-CLDN6 antibody
EP3689911B1 (en) * 2009-11-11 2024-08-21 Astellas Pharma Inc. Antibodies specific for claudin 6 (cldn6)
EP2322555A1 (en) * 2009-11-11 2011-05-18 Ganymed Pharmaceuticals AG Antibodies specific for claudin 6 (CLDN6)
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
EP3026064B1 (en) * 2011-05-13 2018-10-17 Ganymed Pharmaceuticals GmbH Antibodies for treatment of cancer expressing claudin 6
WO2015014376A1 (en) * 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
GB201607534D0 (en) * 2016-04-29 2016-06-15 Immunocore Ltd & Adaptimmune Ltd Peptides
WO2019048040A1 (en) 2017-09-06 2019-03-14 Ganymed Pharmaceuticals Gmbh ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER

Similar Documents

Publication Publication Date Title
US20250223338A1 (en) Non-immunogenic single domain antibodies
RU2017134909A (ru) Новая форма IL33, мутировавшие формы IL33, антитела, анализы и способы их применения
JP2023539245A5 (cg-RX-API-DMAC10.html)
JP2010502183A5 (cg-RX-API-DMAC10.html)
JP2018516853A5 (cg-RX-API-DMAC10.html)
JP2023538945A5 (cg-RX-API-DMAC10.html)
JP2012525829A5 (cg-RX-API-DMAC10.html)
RU2013115927A (ru) АНТИТЕЛА ПРОТИВ ИЛ-1β И СПОСОБЫ ПРИМЕНЕНИЯ
RU2018128215A (ru) Антитела против mica
HRP20191697T1 (hr) Vezujuće molekule za bcma i cd3
RU2018102606A (ru) Молекулы, связывающиеся с psl pseudomonas, и пути их применения
JP2017524362A5 (cg-RX-API-DMAC10.html)
JP2015508056A5 (cg-RX-API-DMAC10.html)
JP2017509323A5 (cg-RX-API-DMAC10.html)
IL294185A (en) Tumor-specific claudin 18.2 antibodies
JP2023549555A5 (cg-RX-API-DMAC10.html)
FI4031569T3 (fi) Kantasolutekijän vasta-aineet ja niiden käyttömenetelmät
JP2022500455A5 (cg-RX-API-DMAC10.html)
JP2021512120A5 (cg-RX-API-DMAC10.html)
JP2023159299A (ja) α-シヌクレインプロトフィブリル結合抗体
JP2019513004A5 (cg-RX-API-DMAC10.html)
JP2024544885A5 (cg-RX-API-DMAC10.html)
WO2022243536A1 (en) Anti il-1 receptor accessory protein antibodies
CN116528909A (zh) 抗肿瘤坏死因子受体(tnfr2)抗体及其用途
WO2022238481A1 (en) Antibodies